Hemogasometry, metabolic profile and acute-phase proteins in primiparous Holstein cows supplemented with butafosfana associated or not of cyanocobalamin

Abstract

The aim of study was to evaluate whether butafosfan, associated or not with cyanocobalamin, alters the metabolic profile, hemogasometrics and acute phase proteins in recent postpartum dairy cows. Twenty-five cows (n ¼ 25) were selected for study and divided into three groups: Butafosfan (BUT, n ¼ 9); Butafosfan þ Cyanocobalamin (BUTC, n ¼ 9); and Control (CTL, n ¼ 7). Treatments were applied daily from calving until 5 days postpartum. Blood samples for hemogasometry were performed on days 0, 1, 2 and 3, and for other metabolites on days 0, 1, 2, 3, 4, 5, 10, 15, 20 and 28 postpartum. Blood pH was lower in the BUT and BUTC groups than in the CTL group (p ¼ .03) and carbon dioxide pressure was higher in the BUT and BUTC groups compared to CTL (p ¼ .01). In addition, ionised calcium levels were higher in the BUT and BUTC groups (p ¼ .0003) in comparison to CTL, whereas the BUT group had higher levels. The BUT group had the lowest levels of paraoxonase (p ¼ .03). On the other hand, glucose levels tended to be highest in the BUT group (p ¼ .08). The butafosfan with or without cyanocobalamin increased ionised calcium levels and tended to stabilise blood pH in the early post-partum cows, and butafosfan without cyanocobalamin tended to increase blood glucose levels. HIGHLIGHTS Treated animals increase serum ionised calcium; Treated animals have a reduction in blood pH; Butafosfan tends to increase the glucose concentration.

Use of organic phosphorous butafosfan and vitamin B12 combination in transition dairy cows

“…In the following reports, butafosfan with or without VB12 combination did not significantly increase phosphorus concentration in the blood of dairy cattle (Rollin et al 2010;Kreipe et al 2011;Pereira et al 2013b;Antunes et al 2019;Scharen et al 2021).…”

“…EMEA (1999) reported that the precise mode of action of butafosfan was unknown. Many of the studies suggest that it is acting pharmacologically as a complete molecule rather than supplying phosphorus to the organism because blood phosphorus concentration was not significantly changed after iBC administrations in cattle (Rollin et al 2010;Kreipe et al 2011;Pereira et al 2013b;Antunes et al 2019;Scharen et al 2021). This is in line with the pharmacokinetic data which confirmed that butafosfan was eliminated rapidly and a mean of 77% of butafosfan was recovered in the urine within 12 h (EMEA 2000).…”

“…However, serum concentration of phosphorus did not increase despite the high dose rate. Antunes et al (2019) reported that butafosfan with or without cyanocobalamin increased ionized calcium levels and tended to stabilise blood pH in early postpartum cows, and butafosfan without cyanocobalamin tended to increase blood glucose concentrations. Another study was conducted in dairy cattle with subclinical ketosis and treated with either injectable butafosfan, iBC or saline (Nuber et al 2016).…”

“…The most recent in vivo biochemical studies conducted on both butafosfan alone or in combination with VB12 (iBC) showed that it interfered with metabolic function and the energy processes in the organism (Hasi et al 2005a;Furll et al 2010;Kreipe et al 2011;Gomes Jose et al 2012;Nuber et al 2016;Antunes et al 2019;Weiller et al 2020;Scharen et al 2021). We identified seven studies about the effect of butafosfan as a single compound in mice (Hasi et al 2004;Hasi et al 2005a;Weiller et al 2020), in poultry (Hasi et al 2005b;Hasi et al 2005c) and in cattle (Nuber et al 2016;Antunes et al 2019).…”

Effects of intravenous butaphosphan and cyanocobalamin to late pregnant ewes on the metabolic indices around parturition and weight gain of their lambs after birth

“…The results showed that the levels of these two enzymes in the B+C3 group were significantly lower than those of the other Ctrl and treatment groups, demonstrating the role of butaphosphan and cyanocobalamin in the health and function of hepatocytes. Liver health plays an important role in preventing metabolic disorders in ruminants, and other researchers have evaluated the effects of this compound on liver health indicators, such as total bilirubin (Antunes et al., 2019 ; Şahal et al., 2017 ; Temizel et al., 2015 ), AST (Pereira et al., 2013 ; Tabele, 2017 ) and gamma‐glutamyl transferase (Pereira et al., 2013 ). Therefore, the use of butaphosphan and cyanocobalamin plays an effective role in reducing the incidence of metabolic disorders by maintaining and promoting liver health and function.…”